Purchase this article with an account.
M. Schellenbeck, V. Müller, S. Lechner, C. Hartmann; Indications for Photodynamic Therapy (PDT) outside the TAP and VIP Trial . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3151.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the safety and the long–term effect on visual acuity of photodynamic therapy (PDT) with verteporfin in the treatment of patients with choroidal neovascularisation (CNV) not secondary to age–related macular degeneration. Methods: Within the last 3 years a total of 47 patients with CNV secondary to pathologic myopia, inflammatory conditions such as multifocal choroiditis and presumed ocular histoplasmosis syndrome (POHS), central serous chorioretinopathy (CSC), autosomal dominat drusen, traumatic CNV and idiopathic causes have been treated with standard PDT and verteporfin. Results: The mean follow–up time is 15.7 months. The mean age of the patients is 37.6 years. A mean of 2.3 treatments (1–5) was performed. 41 out of 47 patients (87.2%) have been stabilized in visual acuity and lost less than 3 lines of visual acuity. 22 patients (46.8%) have improved in visual acuity (1 or more lines) and 14 patients had moderate vision loss of at least 3 lines. No clinically relevant side effects or complications were observed. Conclusions: PDT is a safe and effective treatment option for CNV not related to age–related macular degeneration. A majority of patients remained stable in visual acuity after PDT. Still the treatment of choroidal neovascularisation remains a challenging problem in opththalmology.
This PDF is available to Subscribers Only